纳武单抗用于治疗一名类风湿性关节炎患者的甲氨蝶呤相关性经典型霍奇金淋巴瘤。

Tanaka Keisuke, Kuboki Mai, Koi Satoshi, Toyota Shigeo

Department of Hematology, Yokosuka Kyosai Hospital, Japan.

Intern Med. 2020 Mar 15;59(6):829-833. doi: 10.2169/internalmedicine.3772-19. Epub 2019 Nov 22.

Nivolumab exerts therapeutic activity in patients with classic Hodgkin's lymphoma (CHL) but may cause several types of immune-related adverse events. Some rheumatoid arthritis (RA) patients develop CHL during methotrexate therapy (MTX-CHL); however, the efficacy and safety of nivolumab for these patients remain unclear. A 68-year-old woman was diagnosed with CHL after six years of MTX therapy for RA. The disease did not respond to any type of chemotherapy. Nivolumab was then initiated, and the patient was successfully treated without the reactivation of RA. The reactivation of RA always needs to be considered with the administration of nivolumab.

纳武利尤单抗对经典型霍奇金淋巴瘤（CHL）患者具有治疗活性，但可能会引起几种类型的免疫相关不良事件。一些类风湿关节炎（RA）患者在甲氨蝶呤治疗期间（MTX-CHL）发生CHL；然而，纳武利尤单抗对这些患者的疗效和安全性仍不清楚。一名68岁女性在接受RA的MTX治疗6年后被诊断为CHL。该疾病对任何类型的化疗均无反应。随后开始使用纳武利尤单抗，患者成功接受治疗，RA未复发。使用纳武利尤单抗时始终需要考虑RA的复发情况。